Assessing a compound's activity, not just its structure, could accelerate drug discovery

Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therapies for other diseases.

This action-based focus - called biological activity-based modeling (BABM) - forms the core of a new approach developed by National Center for Advancing Translational Sciences (NCATS) researchers and others.

from Breaking World Pharma News https://ift.tt/3r96IVI